Gender-specific aspects in primary and secondary prevention of cardiovascular disease

Current Pharmaceutical Design

Volumn 17, Issue 11, 2011, Pages 1082-1089

  Mercuro, G ^a   Deidda, M ^a   Bina, A ^a   Manconi, E ^a   Rosano, G M C ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Dyslipidemia; Gender; Primary and secondary prevention

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CYCLOSPORIN; ERYTHROMYCIN; ESTRADIOL; ESTROGEN; FIBRIC ACID DERIVATIVE; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROLIDE; NICOTINIC ACID; PLASMINOGEN; SEX HORMONE; SIMVASTATIN; TRIACYLGLYCEROL; VERAPAMIL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CORONARY ARTERY OBSTRUCTION; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HEART FAILURE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIVER TOXICITY; MALE; META ANALYSIS (TOPIC); MORTALITY; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SEX DIFFERENCE;

EID: 79958231376     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795656954     Document Type: Article

References (97)

1. Mercuro G, Rosano GM. Coronary heart disease in women. Pastgaps and current understanding. Ital Heart J. 2003; 4(8): 505-7.
2. Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relationof overweight to cardiovascular risk factors among childrenand adolescents: the Bogalusa Heart Study. Pediatrics 1999; 103:1175-82.
3. De Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of the metabolic syndrome in American adolescents. Findings from the Third National Health and Nutrition Examination Survey. Circulation 2004; 110: 2494-7.
4. Ford ES, Mokdad AH, Ajani UA. Trends in risk factors for cardiovasculardisease among children and adolescents in the UnitedStates. Pediatrics 2004; 114: 1534-44.
5. Centers for Disease Control and Prevention. Trends in cholesterolscreening and awareness of high blood cholesterol - UnitedStates, 1991-2003. MMWR Morb Mortal Wkly Rep 2005; 54:865-70.
6. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoproteinlevels as predictors of cardiovascular death in women. Arch InternMed 1993; 153: 2209-16.
7. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoproteincholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-1and B, and HDL density subfractions: the Atherosclerosis Risk inCommunities (ARIC) Study. Circulation 2001; 104: 1108-13.
8. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD et al. High-density lipoprotein cholesterol and cardiovasculardisease: four prospective American studies. Circulation 1989; 79: 8-15.
9. Krauss RM. Dense low density lipoproteins and coronary arterydisease. Am J Cardiol 1995; 75: 53B-7B.
10. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factorfor cardiovascular disease independent of high-density lipoproteincholesterol level: a meta-analysis of population-based prospectivestudies. J Cardiovasc Risk 1996; 3: 213-9
11. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR et al. Declining serum total cholesterol levels amongUS adults: the National Health and Nutrition Examination Surveys. JAMA 1993; 269: 3002-8.
12. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statementfor healthcare professionals from the American Heart AssociationWriting Group. Circulation 1997; 96: 2468-82.
13. Jensen J, Nilas L, Christiansen C. Influence of menopause on serumlipids and lipoproteins. Maturitas 1990; 12: 321-31.
14. Austin M, Breslow J, Hennekens C, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardialinfarction. JAMA 1988; 260: 1917-21.
15. Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, et al. Low density lipoprotein particle size and coronaryartery disease. Arterioscler Thromb 1992: 12: 187-95.
16. Mercuro G, Zoncu S, Dragoni F. Gender differences in cardiovascularrisk factors. Ital Heart J. 2003 Jun; 4(6): 363-6.
17. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoproteinparticle concentration and size as determined by nuclear magneticresonance spectroscopy as predictors of cardiovascular disease inwomen. Circulation. 2002 Oct 8; 106(15): 1930-7.
18. Poehlman ET, Toth MJ, Gardner AW. Changes in energy balanceand body composition at menopause: a controlled longitudinalstudy. Ann Intern Med 1995; 123: 673-5.
19. Razay G, Heaton KW, Bolton CH. Coronary heart disease riskfactors in relation to the menopause. Q J Med 1992; 85: 889-96.
20. Li Z, McNamara JR, Fruchart JC, Luc G, Bard JM, Ordovas JM et al. Effects of gender and menopausal status on plasma lipoproteinsubspecies and particle sizes. J Lipid Res 1996; 37: 1886-96.
21. Campos H, McNamara JR, Wilson PW, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteinsin premenopausal and postmenopausal women. J Clin EndocrinolMetab 1988: 67: 30-5.
22. Stevenson JC, Crook D, Godsland IF. Influence of age and menopauseon serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90.
23. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronaryheart disease. The Framingham Study. Am J Med. 1977; 62: 707-14.
24. Boden WE. High-density lipoprotein cholesterol as an independentrisk factor in cardiovascular disease: assessing the data fromFramingham to the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol. 2000; 86: 19L-22L.
25. Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospectivestudies on the relationship between high-density lipoproteincholesterol and cardiovascular risk: a systematic review. Eur J CardiovascPrev Rehabil. 2009; 16(4): 404-23.
26. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, et al. Estrogen and progestin, lipoprotein(a), and therisk of recurrent coronary heart disease events after menopause. JAMA 2000; 283: 1845-52.
27. Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PW, Castelli WP, et al. Effects of age, sex, and menopausal status onplasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 1993; 87: 1135-41.
28. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-based guidelines for cardiovasculardisease prevention in women. Circulation. 2004; 109: 672-93.
29. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primaryprevention of coronary heart disease in women through diet andlife- style. N Engl J Med. 2000; 343: 16-22.
30. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-lino- lenic acid-rich diet in secondaryprevention of coronary heart disease. Lancet. 1994; 343: 1454-9.
31. Leren P. Prevention of coronary heart disease: some results fromthe Oslo secondary and primary intervention studies. J Am CollCardiol. 1989; 8: 407-10.
32. Long-term Intervention with Pravastatin in Ischaemic Disease(LIPID) Study Group. Prevention of cardiovascular events anddeath with pravastatin in patients with coronary heart disease and abroad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-57.
33. Lewis SJ, Sacks FM, Mitchell JS, Glasser S, Kell S, et al. for theCARE Investigators. Effect of pravastatin on cardiovascular eventsin women after myocar- dial infarction: the cholesterol and recurrentevents (CARE) trial. J Am Coll Cardiol. 1998; 32: 140-6.
34. Miettinen TA, Pyörälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, et al. for the Scandinavian Simvastatin Study Group.Cholesterol-lowering therapy in women and elderly patients withmyocardial infarction or angina pectoris: findings from the ScandinavianSimvastatin Survival Study (4S). Circulation. 1997; 96:4211-8.
35. Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, et al. Air Force/Texas Coronary At- herosclerosis PreventionStudy (AFCAPS/TexCAPS): efficacy and toler- ability of longtermtreatment with lovastatin in women. J Womens Health GendBased Med. 2001; 10: 971-81.
36. Heart Protection Study Collaborative Group. MRC/BHF HeartProtection Study of cholesterol lowering with simvastatin in 20 536high- risk individuals: a randomised placebo-controlled trial. Lancet.2002; 360: 7-22.
37. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. for the Air Force/Texas Coronary Atherosclerosis PreventionStudy. Primary prevention of acute coronary events withlovastatin in men and women with average cholesterol levels: resultsof AFCAPS/TexCAPS. JAMA. 1998; 279: 1615-22.
38. Scandinavian Simvastatin Survival Study Group. Randomised trialof cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet.1994; 344: 1383-9.
39. Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC for the HARP Research Group. Controlled trial of fish oilfor re- gression of human coronary atherosclerosis. J Am Coll Cardiol.1995; 25: 1492-8.
40. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. on behalf of the PROSPER study group. Pravastatinin elderly individuals at risk of vascular disease (PROSPER):a randomised controlled trial. Lancet. 2002; 360: 1623-30.
41. Sever PS, Dahlo f B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. for the ASCOT Investigators. Prevention of coronary andstroke events with atorvastatin in hyper- tensive patients who haveaverage or lower-than-average cholesterol concentrations, in theAnglo-Scandinavian Cardiac Outcomes Trial- Lipid LoweringArm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149-58.
42. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic,hypertensive patients randomized to pravastatinvs usual care: the Antihypertensive and Lipid-lowering Treatmentto Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288: 2998-3007.
43. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. for the Pravastatin or Atorvastatin Evaluation andInfection Therapy-thrombolysis in Myocardial Infarction 22 Investigators.Intensive versus moderate lipid lowering with statins afteracute coronary syndromes. N Engl J Med. 2004; 350: 1495-504.
44. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronarydisease: a meta-analysis of randomized controlled trials. JAMA.1999; 282(24): 2340-6.
45. Expert Panel on Detection, Evaluation, and Treatment of HighBlood Cholesterol in Adults. Third report of the National CholesterolEducation Program [NCEP] Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III]: final report. Circulation 2002; 106:3143-421.
46. Goldberg AC. A meta-analysis of randomized controlled studies onthe effects of extended-release niacin in women. Am. J. Cardiol.2004; 94: 121-4.
47. Walsh J.M.E., Pignone M. Drug treatment of hyperlipidemia inwomen. J. Am. Med. Ass. 2004; 291: 2243-52.
48. Rosenberg H., Allard D. Women and statin use: a women's health advocacy perspective. Scand. Cardiovasc. J. 2008; 42: 268-274.
49. Rosenberg H, Allard D, "Evidence for Caution: Women and Statin Use," Women and Health Protection, Health Canada, June 2007. http://www.whp-apsf.ca/pdf/statinsEvidenceCaution.pdf
50. Kapur N.H., Musunuru K., Clinical efficacy and safety of statins inmanaging cardiovascular risk. Vascul. Health Risk Manag. 2008; 4:345-353.
51. Kenis I., Tartakover-Matalon S, Cherepnin N, Drucker L, Fishman A, Pomeranz M, et al. Simvastatin has deleterious effects on humanfirst trimester placental explants. Hum. Reproduct. 2005; 20:2866-2872.
52. The Coronary Drug Project Research Group. Clofibrate and niacinin coronary heart disease. JAMA. 1975; 231: 360-81.
53. Canner PL, Furberg CD, McGovern ME. Niacin decreases myocardialinfarction and total mortality in patients with impaired fastingglucose or glucose intolerance: results from the Coronary Drug Project. Circu- lation. 2002; 106(suppl II): II-636; Abstract 3138.
54. Rubins HB, Robins SJ, Collins D, ye CL, Anderson JW, Elam MB, et al. for the Veterans Affairs High- density Lipoprotein CholesterolIntervention Trial Study Group. Gemfibrozil for the secondaryprevention of coronary heart disease in men with low levels ofhigh-density lipoprotein cholesterol. N Engl J Med. 1999; 341:410-8.
55. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-pre- vention trial with gemfibrozilin middle-aged men with dyslipidemia. Safety of treatment,changes in risk factors, and incidence of coronary heart disease. NEngl J Med. 1987; 317: 1237-45.
56. Carlson LA, Rosenhamer G. Reduction of mortality in the StockholmIschaemic Heart Disease Secondary Prevention Study bycombined treatment with clofibrate and nicotinic acid. Acta MedScand. 1988; 223: 405-18.
57. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxi- dant vitamins, or the combinationfor the prevention of coronary disease. N Engl J Med.2001; 345: 1583-92.
58. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familialhypercholesterolemia with combined drug regimens. JAMA. 1990;264: 3007-12.
59. Genest J, Frohlich J, Fodor G, McPherson R; Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendationsfor the management of dyslipidemia and the prevention of cardiovasculardisease: summary of the 2003 update. CMAJ 2003; 169:921-4.
60. Yaari S, Goldbourt, Even-Zohar S, Neufeld HN. Associations ofserum high density lipoprotein and total cholesterol with total, cardiovascular,and cancer mortality in a 7-year prospective study of10 000 men. Lancet. 1981 May 9; 1(8228): 1011-5.
61. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronaryheart disease. The Framingham Study. Am J Med. 1977; 62: 707-14.
62. Castelli WP, Anderson K, Willson PW, Levy D. Lipids and risk ofcoronary heart disease: the Framingham Study. Ann Epidemiol 1992; 2: 23-8.
63. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al.; Treating to New Targets Investigators. HDL cholesterol,very low levels of LDL cholesterol, and cardiovascular events. NEngl J Med. 2007; 357(13): 1301-10.
64. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heartdisease risk in the Helsinki Heart Study. Implications for treatment.Circulation. 1992; 85(1): 37-45.
65. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence ofischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol. 1997 Jun; 17(6):1114-20.
66. Gotto AM Jr. Triglyceride: the forgotten risk factor. Circulation.1998; 97(11): 1027-8.
67. Howard BV, Abbott WG, Egusa G, Taskinen MR. Coordination ofvery low-density lipoprotein triglyceride and apolipoprotein B metabolismin humans: effects of obesity and non-insulin-dependentdiabetes mellitus. Am Heart J. 1987; 113: 522-6.
68. Laakso M, Sarlund H, Mykkänen L. Insulin resistance is associatedwith lipid and lipoprotein abnormalities in subjects with varyingdegrees of glucose tolerance. Arteriosclerosis. 1990; 10(2): 223-31.
69. Lamarche B, Lewis GF. Atherosclerosis prevention for the nextdecade: risk assessment beyond low density lipoprotein cholesterol. Can J Cardiol. 1998; 14(6): 841-51.
70. Vohl MC, Tchernof A, Dionne FT, Moorjani S, Prud'homme D, Bouchard C, et al. The apoB-100 gene EcoRI polymorphism influencesthe relationship between features of the insulin resistancesyndrome and the hyper-apoB and dense LDL phenotype in men. Diabetes. 1996 Oct; 45(10): 1405-11.
71. Kris-Etherton PM, Harris WS, Appel LJ for the Nutrition Committee.Fish consumption, fish oil, omega-3 fatty acids, and cardiovasculardisease. Circulation. 2002; 106: 2747-57.
72. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infartomiocardico. Dietary supplementation with n-3 polyunsaturatedfatty acids and vitamin E after myocardial infarction: results of theGISSI-Prevenzione trial. Lancet. 1999; 354: 447-55.
73. Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC for the HARP Research Group. Controlled trial of fish oilfor regression of human coronary atherosclerosis. J Am Coll Cardiol.1995; 25: 1492-8.
74. Nilsen DW, Albrektsen G, Landmark K, Moen S, Aarsland T, Woie L. Effects of a high-dose concentrate of n-3 fatty acids orcorn oil introduced early after an acute myocardial infarction on serumtriacylglycerol and HDL cholesterol. Am J Clin Nutr. 2001;74: 50-6.
75. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the NationalCholesterol Education Program Adult Treatment Panel IIIGuidelines. Circulation. 2004; 110: 227-39.
76. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the useand safety of statins. J Am Coll Cardiol. 2002; 40: 567-72.
77. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett. 2002; 128(1-3): 159-68.
78. Lipid Research Clinics Program. The Lipid Research Clinics CoronaryPrimary Prevention Trial results. I. Reduction in incidence ofcoronary heart disease. JAMA. 1984; 251: 351-64.
79. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341: 498-511.
80. Gupta EK, Ito MK. Lovastatin and extended-release niacin combinationproduct: the first drug combination for the management ofhyperlipidemia. Heart Dis. 2002; 4: 124-37.
81. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia-currenttherapies and future agents. Expert Opin Pharmacother. 2003; 4:1901-38.
82. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. for the Ezetimibe Study Group. Efficacy and safety of ezetimibeadded to ongoing statin therapy for treatment of patients with primaryhypercholesterolemia. Am J Cardiol. 2002; 90: 1084-91.
83. Jacobson TA, Jokubaitis LA, Amorosa LF. Fluvastatin and niacinin hypercholesterolemia: a preliminary report on gender differencesin efficacy. Am J Med. 1994; 96: 64S-68S.
84. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy andsafety of ezetimibe coadministered with simvastatin in patientswith primary hypercholesterolemia: a randomized, double-blind,placebo- controlled trial. Mayo Clin Proc. 2004; 79: 620-9.
85. Capuzzi DM, Morgan JM, Brusco OAJ, Intenzo CM. Niacin dosing:relationship to benefits and adverse effects. Curr AtherosclerRep. 2000; 2: 64-71.
86. Whelan AM, Price SO, Fowler SF, Hainer BL. The effect of aspirinon niacin-induced cutaneous reactions. J Fam Pract. 1992; 34: 165-8.
87. Maccubbin D, Bays HE, Olsson AG, Elinoff V, Elis A, Mitchel Y, et al. Lipid-modifying efficacy and tolerability of extended-releaseniacin/laropiprant in Patients with primary hypercholesterolaemiaor mixed dyslipidaemia. Int J Clin pract. 2008; 62: 1959-70.
88. Maccubbin D, Koren MJ, Davidson M, Gavish D, Pasternak RC, Macdonell G, et al. Flushing profile of extended-release niacin/laropiprantversus extended-release niacin titrated gradually in Patientswith dyslipidemia with and without ischemic CVD. Am JCardiol. 2009; 104 (1): 74-81
89. Fruchart JC, Brewer HB Jr, Leitersdorf E. Consensus for the use offibrates in the treatment of dyslipoproteinemia and coronary heartdisease. Fibrate Consensus Group. Am J Cardiol. 1998; 81(7): 912-7
90. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother.2001; 35: 908-17.
91. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. for the Heart and Estrogen/Progestin Replacement Study(HERS) Research Group. Randomized trial of estrogen plus progestinfor secondary prevention of coronary heart disease in postmenopausalwomen. JAMA. 1998; 280: 605-13.
92. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. for the Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plusprogestin in healthy postmenopausal women: principal results fromthe Women's Health Initiative randomized controlled trial. JAMA.2002; 288: 321-33.
93. The Women's Health Initiative Steering Commitee. Effects ofconjugated equine estrogen in post-menopausal women with hyster-ectomy. The Women's Health Initiative Randomized Controlled Trail. JAMA. 2004; 291(14): 1701-1712 (doi:10.1001/jama.291.14.1701).
94. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-Based Guidelines for Cardiovascular Disease Preventionin Women: 2007 Update. Circulation 2007; 115; 1481-501.
95. Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC Jr, Havas S, et al. ACCF/AHA 2009 performance measures for primary preventionof CVD in adults: a report of the American College of CardiologyFoundation/American Heart Association task force on performancemeasures (writing committee to develop performancemeasures for primary prevention of cardiovascular disease): developedin collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's HealthResearch. Circulation. 2009; 120(13): 1296-336.
96. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid TreatmentAs- sessment Project (L-TAP): a multicenter survey to evaluate thepercent- ages of dyslipidemic patients receiving lipid-loweringtherapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160: 459-67.
97. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, et al. A national study of physician awarness and adherence tocardiovascular disease preven- tion guidelines. Circulation 2005;111: 499-510.